Category: Treatment in China

Home / Established Year

First Gene Therapy for Children with Metachromatic Leukodystrophy is Approved by the FDA

First Gene Therapy for Children with Metachromatic Leukodystrophy is Approved by the FDA

FDA approval The U.S. Food and Drug Administration has granted Lenmeldy (atidarsagene autotemcel) approval. The FDA has approved this gene therapy as the first of its kind for the treatment of children with pre-symptomatic late i..

FDA approves gene therapy to treat beta thalassemia

FDA approves gene therapy to treat beta thalassemia

FDA approval of gene therapy The FDA has made it possible for people 12 years of age and older who have transfusion-dependent beta-thalassemia (TDT) to use exagamglogene autotemcel (Casgevy, Vertex). This is a cell therapy that c..

Gene Therapy for Thalassemia

Gene Therapy for Thalassemia

Gene Therapy Applied to Thalassemia: An Overview Thalassemia is one such blood disorder characterized by the body being unable to produce enough hemoglobin, making life unusually challenging for both patients and healthcare provi..

Gene therapy for sickle cell anemia

Gene therapy for sickle cell anemia

Gene Therapy for Sickle Cell Anemia: An Introduction Gene therapy for sickle cell anemia has been one of the most promising methodologies in the treatment of this genetic disorder. This article takes one deep into the world of ge..

Mesenchymal Stem Cell Therapy In Neurological Disorders

Mesenchymal stem cell therapy in neurological disorders

Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..

Stem Cell Therapy for Diabetes

Stem Cell Therapy for Diabetes: A Promising Treatment Approach

March 2024: Stem cell therapy has emerged as a promising treatment option for diabetes mellitus, potentially addressing the obstacles that patients encounter. Research in this field has investigated various types of stem cells, ..

jw-therapeutics
, , , , ,

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy